NetworkNewsBreaks – Soligenix Inc.’s (NASDAQ: SNGX) SGX945 Shows Promise with Immune-Modulating Approach
Soligenix (NASDAQ: SNGX) was featured in a recent article that discussed the company’s release of positive top-line results from its phase 2 clinical trial evaluating SGX945 for the treatment of aphthous ulcers associated with Behçet’s. “Behçet’s disease is a rare, chronic inflammatory condition that can cause recurrent, painful ulcers, eye inflammation and systemic complications that significantly affect quality of life. Because available treatments are limited and often inconsistent, clinical trial updates in this disease area carry particular importance. Soligenix is reporting results from a phase 2a proof of concept study evaluating its investigational therapy, SGX945 (dusquetide), for the treatment of Behçet’s disease, representing a notable step forward in efforts to improve care for patients with this underserved condition… SGX945 is a novel innate defense regulator designed to modulate the body’s immune response rather than broadly suppress it. Soligenix explains that this mechanism aims to reduce harmful inflammation while preserving the immune system’s ability to fight infection, a critical distinction from many existing immunosuppressive therapies. In the phase 2 study, SGX945 was reported to be safe and well tolerated, an important consideration for a chronic disease requiring repeated or long-term treatment.”
For further information, visit the company’s website at www.Soligenix.com.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://nnw.fm/SNGX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Soligenix (NASDAQ: SNGX) was featured in a recent article that discussed the company’s release of positive top-line results from its phase 2 clinical trial evaluating SGX945 for the treatment of aphthous ulcers associated with Behçet’s. “Behçet’s disease is a rare, chronic inflammatory condition that can cause recurrent, painful ulcers, eye inflammation and systemic complications that significantly affect quality of life. Because available treatments are limited and often inconsistent, clinical trial updates in this disease area carry particular importance. Soligenix is reporting results from a phase 2a proof of concept study evaluating its investigational therapy, SGX945 (dusquetide), for the treatment of Behçet’s disease, representing a notable step forward in efforts to improve care for patients with this underserved condition… SGX945 is a novel innate defense regulator designed to modulate the body’s immune response rather than broadly suppress it. Soligenix explains that this mechanism aims to reduce harmful inflammation while preserving the immune system’s ability to fight infection, a critical distinction from many existing immunosuppressive therapies. In the phase 2 study, SGX945 was reported to be safe and well tolerated, an important consideration for a chronic disease requiring repeated or long-term treatment.”
For further information, visit the company’s website at www.Soligenix.com.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://nnw.fm/SNGX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
